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Abstract. Glioblastoma (GB) is the most aggressive type of 
primary brain tumor. Despite the progress in recent years 
regarding the diagnosis and treatment of GB, the recurrence 
rate remains high, due to the infiltrative and dispersive nature 
of the tumor, which typically results in poor patient prognosis. 
In the present study, 19 formalin-fixed, paraffin-embedded 
GB samples were selected from patients with GB tumors. The 
samples were classified into a short or long recurrence‑free 
survival (RFS) group, based on the time of first recurrence of the 
disease in the patients. The 19 samples were molecularly char-
acterized for mutations in the isocitrate dehydrogenase 1 (IDH1) 
gene, amplification of the epidermal growth factor receptor 
(EGFR) gene, presence of the EGFR variant III, and meth-
ylation of the promoter region of the O6-methylguanine-DNA 
methyltransferase (MGMT) gene. Then, the expression of 
84 genes involved in cell-cell and cell-matrix interactions, and 
that of 84 microRNAs (miRNAs) associated with brain cancer, 
was profiled. In addition, a copy number variation analysis of 
23 genes reported to undergo frequent genomic alterations in 
human glioma was also performed. Differences in the expres-
sion levels of a number of genes were detected across the short 
and long RFS groups. Among these genes, 5 in particular were 
selected, and a 5-genes combination approach was developed, 
which was able to differentiate between patients with short and 
long RFS outcome. The high levels of sensitivity and precision 
displayed by this 5-genes combination approach, which were 
confirmed with a cross-validation method, provide a strong 
foundation for further validation of the involvement of the 
aforementioned genes in GB in a larger patient population. In 
conclusion, the present study has demonstrated how the expres-
sion pattern of miRNAs and mRNAs in patients with GB defines 
a particular molecular hallmark that may increase or reduce the 
aggressive behavior of GB tumors, thus influencing the survival 
rates of patients with GB, their response to therapy and their 
tendency to suffer a relapse.
Introduction
Glioblastoma (GB) is the most common and aggressive type 
of malignant primary brain tumor. The current standard of 
care for GB, as established by Stupp et al (1), is maximal safe 
surgical resection, followed by temozolomide chemotherapy 
and radiation. This current standard therapeutic regimen 
has increased the median survival rate of patients with GB 
to 12.1-14.6 months, with a median 2-years survival rate of 
26% (2). However, mortality from GB inevitably occurs, due 
to the recurrence or progression of the disease (3). Previous 
studies have indicated that recurrence of GB is unavoidable, 
following a median survival time of 8-9 months (3). Once a 
patient with GB relapses following initial surgery, radiotherapy 
and chemotherapy, the salvage strategies available are often 
limited, and the survival time is short (4,5). This is most likely 
due to molecular and genetic alterations within the tumor 
itself, or as a consequence of preceding therapies (3).
Therefore, novel therapeutic approaches to treat GB, and 
scientific and clinical advances in the treatment of this disease 
are required. The identification of molecular biomarkers for 
the management and monitoring of patients with cancer may 
improve their clinical outcome. Numerous biomarker candi-
dates have been generated by high-throughput technologies, 
which are powerful and promising methods for evaluating the 
expression of a large number of genes and detecting alterations 
in genome-wide expression analyses (6). An important aspect 
of GB invasion is the elaboration by the tumor cells of a migra-
tion-enhancing extracellular matrix (ECM), and the secretion 
of proteolytic enzymes that permit cell invasion through this 
matrix (7). This hypothesis is consistent with previous gene 
expression profiling studies, which identified a subset of 
tumors with increased expression of ECM components and 
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intracellular proteins associated with cell motility (8,9). The 
interplay between the various matrix and growth factor recep-
tors, and the activation of signaling pathways that facilitate 
the invasion of tumor cells, has been recently recognized as a 
composite, dynamic consequence of altered cell-cell adhesion, 
proteolytic remodeling and synthesis of ECM, and selective 
expression and activation of integrins (10). Furthermore, in the 
past few years, several signaling pathways have been associated 
with reduced sensitivity of GB cells to radiation and chemo-
therapy (11). Numerous genes involved in these pathways have 
been demonstrated to be regulated by microRNAs (miRNAs), 
which are important regulators in cancer cell biology, and 
promising biomarkers or therapeutic targets in GB (11,12).
However, despite all the molecular information on GB 
gathered thus far, the optimal management of patients with GB 
remains elusive, due to the absence of validated data from clinical 
studies, and the great heterogeneity of this fragile subpopula-
tion, in terms of their physical condition, co-morbidity status, 
tolerance to treatment and clinical prognosis (13). The invasive 
nature of GB growth and its fast proliferation rate are the major 
reasons for therapeutic failure in patients with GB (14). There-
fore, a detailed characterization of the molecular mechanisms 
involved in the development of GB is required, in order to 
improve the accuracy of the prediction models, regarding the 
prognosis and response to therapies in patients with GB.
In order to improve the understanding of the dynamics of 
the genomic alterations associated with tumor relapse, and to 
provide novel information on the aggressive behavior of GB 
tumors, primary GB tumors of patients with GB displaying 
short or long recurrence-free survival (RFS) outcome, were 
molecularly characterized and compared in the present study.
In particular, 19 GB samples were characterized according 
to the presence of mutations in the isocitrate dehydrogenase 1 
(IDH1) gene, amplification of the epidermal growth factor 
receptor (EGFR) gene, presence of the EGFR variant III 
(EGFRvIII), and methylation of the promoter region of the 
O6-methylguanine-DNA methyltransferase (MGMT) gene. 
Furthermore, the expression of 84 genes known to be impor-
tant for cell-cell and cell-matrix interactions, and that of 
84 miRNAs known to switch their expression pattern during 
nervous system-associated carcinogenesis, were profiled. In 
addition, a copy number variation analysis of 23 genes, whose 
expression has been previously reported to be frequently 
altered in human glioma tumors (15), was also performed.
Table I. Demographic characteristics of the patient population at the time of diagnosis, and molecular characterization of the 
glioblastoma tumors.
Patient features at diagnosis Overall, n (%) Short RFS, n (%) Long RFS, n (%)
Total (n) 19 10 9
Gender 
  Female 10 (53) 6 (60) 4 (44)
  Male  9 (47) 4 (40) 5 (56)
Age 
  Mean ± standard deviation 60±6.9 63±6.2 58±6.8
  <60 years  9 (47) 4 (40) 5 (56)
  ≥60 years 10 (53) 6 (60) 4 (44)
Molecular alterations
  EGFR
    wt 10 (53) 7 (70) 3 (33)
    ampl  9 (44) 3 (30) 6 (67)
  EGFRvIII in EGFR ampl
    Yes 3 (33) 1 (33) 2 (33)
    No 6 (67) 2 (67) 4 (67)
  MGMT
    wt 11 (58) 5 (50) 6 (67)
    met  8 (42) 5 (50) 3 (33)
  IDH1
    wt  19 (100) 10 (100) 9 (100)
    mut 0 (0) 0 (0) 0 (0)
Patients displaying EGFR wt were characterized by no alterations in the copy number of the EGFR gene, whereas those exhibiting EGFR 
ampl presented a high copy number of EGFR. Patients with EGFRvIII carried the constitutively active genomic deletion variant III of EGFR, 
characterized by the deletion of exons 2-7 in the EGFR gene. MGMT wt indicated absence of methylation in the promoter CpG islands of the 
MGMT gene, contrarily to the case of patients with MGMT met. Patients were classified as IDH1 wt or IDH1 mut, based on the absence or 
presence of mutations in the codon 132 of the IDH1 gene, respectively. RFS, recurrence-free survival; EGFR, epidermal growth factor receptor; 
wt, wild‑type; ampl, amplification; EGFRvIII, EGFR variant III; MGMT, O(6)‑methylguanine-DNA methyltransferase; met, methylation; 
CpG, cytosine-phosphate-guanine; IDH1, isocitrate dehydrogenase 1; mut, mutation.
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Materials and methods
Patients and tumors. The present study included 19 newly 
diagnosed cases of GB, who presented to the Department 
of Translational Research and of New Surgical and Medical 
Technologies of the University Hospital of Pisa (Pisa, Italy). 
The patients, who were initially diagnosed by resection with 
GB grade IV (according to the World Health Organization 
classification criteria) (16), did not present any previous 
record of brain neoplasm. The GB tumors isolated from the 
patients were stored as formalin-fixed, paraffin-embedded 
(FFPE) specimens.
The GB cases included in the present study were selected 
according to their differences in progression-free survival. Of 
the 19 included GB cases, 10 cases, were classified as ‘short 
RFS’ and first displayed recurrence earlier than 6 months, 
and 9 cases, were classified as ‘long RFS’ and first displayed 
recurrence later than 14 months.
The median age of the patients was 61 years, and the gender 
distribution was 9/19 (47%) males and 10/19 (53%) females. 
The short RFS GB patients presented a median age of 
63 years; gender distribution of 4/10 (40%) males and 
6/10 (60%) females; and a mean RFS of 4.5 months, 
ranging from 2 to 6 months. The long RFS GB patients 
presented a median age of 58 years; gender distribution of 
4/9 (44%) males and 5/9 (56%) females; and a mean RFS 
of 27 months, ranging between 14 and 71 months (Table I). 
The information regarding the size of the tumors and their 
localization within a certain brain region in relation to the 
duration of RFS is presented in Table II.
Ethical board. The present study was approved by the Internal 
Review Board of the University Hospital of Pisa. All patients 
provided their consent for participation in the study.
DNA and RNA extraction. DNA and RNA were extracted from 
2 10-µm sections of each FFPE specimen, using NucleoSpin 
Tissue (Machery-Nagel, Düren, Germany) and RNeasy FFPE 
Kit (Qiagen GmbH, Hilden, Germany) to extract the genomic 
DNA and total RNA from the tissues, respectively. The 
extracted DNA and RNA were quantified using Qubit 2.0 Fluo-
rometer (Life Technologies, Grand Island, USA), according to 
the manufacturer's instructions. The DNA and RNA yields 
ranged from 50 to 500 ng/µl.
Molecular markers. The samples were molecularly charac-
terized by investigating the most studied molecular markers 
alterations in GB tumors, including mutations in the IDH1 gene; 
amplification of the EGFR gene; presence of EGFRvIII, the 
active mutant variant form of the EGFR gene; and methylation 
of the MGMT promoter:
IDH1 mutation. For the detection of IDH1 mutations, 
Primer3 software (http://primer3.ut.ee/) was used to design 
the following primers, in order to amplify the exon 4 of the 
IDH1 gene: Forward, 5'-AGC TCT ATA TGC CAT CAC TGC-3'; 
and reverse, 5'-TTC ATA CCT TGC TTA ATG GGT GT-3'). Poly-
merase chain reaction (PCR) amplification was performed 
with AmpliTaq Gold DNA Polymerase with Buffer II and 
MgCl2 (Life Technologies), according to the manufacturer's 
protocol. The PCR products were loaded onto a 2% agarose gel, 
subjected to DNA gel electrophoresis, stained with ethidium 
Table II. Brain region localization, size (height x width x length) and area of the glioblastoma tumors in the short (n=10) and 
long (n=9) RFS cohorts.
Surgical pathology number RFS group Brain region Tumor size (cm) Tumor area (cm2)
298/09 Short Parietal 4.0x3.0x2.0  52
476/06 Long Righ temporal 5.5x5.0x2.0  97
2102/08 Long N/A 2.0x1.5x1.0  13
3605/06 Short Left frontal 5.8x4.5x3.0 114
4096/10 Short Frontal 4.5x4.0x2.0  70
4239/12 Short Right temporal 4.0x2.5x1.0  33
4318/07 Long Frontal 2.5x2.5x2.0  33
4382/05 Short Right insula 1.4x1.0x0.8   7
4534/11 Long N/A 3.0x2.0x0.5  17
4561/12 Long N/A 5.0x2.0x0.3  24
4619/07 Long Frontal 1.2x0.6x0.5   3
5165/11 Long N/A 2.0x1.5x1.0   13
6043/08 Long N/A 5.0x5.0x2.0  90
7031/07 Long Basal temporal lobe 4.5x3.5x1.0  48
7624/05 Short Right temporoparietal 4.0x3.6x1.7  55
7901/09 Short Left pre-rolandic (frontal) 4.0x2.0x1.0  28
9298/07 Short Right frontal 6.5x5.0x3.5 146
9303/09 Short N/A 2.5x2.0x0.5 + 3.0x3.0x0.5  27
10504/10 Short N/A 4.0x3.0x1.5  45
RFS, recurrence-free survival; N/A, not available.
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bromide and verified by sequencing. For this purpose, the PCR 
bands were excised from the gel and purified using QIAquick 
Gel Extraction Kit (Qiagen GmbH), prior to being subjected to 
direct sequencing in both directions with the aforementioned 
primers, using the BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems Life Technologies, Foster City, USA). 
The sequencing reaction was conducted on an ABI PRISM 
3130xl Genetic Analyzer (Applied Biosystems Life Technolo-
gies), according to the manufacturer's protocol.
Copy number variation. Analyses of the number of copies 
of the EGFR gene and the presence of the EGFRvIII variant 
were performed with SALSA MLPA P105 Glioma-2 probemix 
(MRC-Holland, Amsterdam, The Netherlands), according to 
the manufacturer's protocol. Fragment analysis was performed 
on an ABI PRISM 3130xl Genetic Analyzer (Applied Biosys-
tems Life Technologies).
MGMT promoter methylation. Analysis of the methylation 
status of the MGMT promoter was performed with the MGMT 
plus kit (Diatech Pharmacogenetics, Jesi, Italy), according to 
the manufacturer's instructions. Following bisulfite conver-
sion, the DNA was amplified with bisulfite-specific primers, 
using TaKaRa Ex Taq Hot Start DNA Polymerase (Clontech 
Laboratories, Inc., Mountainview, USA), according to the 
manufacturer's protocol, and analyzed on a PyroMark Q96 ID 
(Qiagen GmbH), using Pyro Q-CpG software (Qiagen GmbH).
PCR commercial arrays
ECM and adhesion molecules. 100 ng of isolated RNA was 
reverse transcribed to cDNA, and pre-amplified using the RT2 
PreAMP cDNA Synthesis Kit (Qiagen GmbH). The cDNA was 
aliquoted with Mastermix (Qiagen GmbH) and added to the 
wells of an ECM microarray plate (catalogue no. PAHS-0013; 
SABiosciences, Frederick, USA), according to the manufac-
turer's instructions.
Brain cancer miRNA. 250 ng of isolated RNA was reverse 
transcribed to cDNA using miScript II RT Kit (Qiagen GmbH). 
The cDNA generated was subsequently used as a template for 
qPCR, using the miScript SYBR Green PCR Kit (SABiosci-
ences, Qiagen GmbH) and the Human Brain Cancer miRNA 
PCR Array (catalogue no. MIHS-108Z; SABiosciences), 
according to the manufacturer's instructions.
Glioma copy number. 800 ng of extracted DNA was 
aliquoted with qBiomarker SYBR Mastermix (Qiagen GmbH, 
Hilden, Germany) and added to the wells of a Human Glioma 
Copy Number PCR Array Plate (catalogue no. VAHS-0053Z, 
SABiosciences), according to the manufacturer's instructions.
All the above PCR array analyses were performed 
calculating the ΔCT value for each gene profiled in the plate, 
using the formula ΔCT = CT (gene of interest) - average CT 
(reference gene). The fold difference value, used for statistical 
analysis, was equated to 2–ΔΔCT.
Statistical analyses. The χ2 test was used to establish whether 
there was any association between the 2 categorical variables, 
short/long RFS group, and any alterations in molecular 
markers, including mutations in the IDH1 gene, EGFR amplifi-
cation, presence of the mutant form EGFRvIII and methylation 
of the MGMT promoter. Differences in the gene expression 
levels between the 2 groups were analyzed by one-way 
analysis of variance. Discriminant analysis was conducted to 
predict the probability of a particular sample to belong to the 
short or the long RFS group, based on the expression levels of 
the profiled genes exhibited by the sample.
Principal component analysis (PCA) was used to convert 
a set of observations of possibly correlated variables (gene 
expression levels) into a set of values of linearly uncorrelated 
variables termed PCs. PCs are guaranteed to be independent 
if the data set is jointly normally distributed (17). A tridi-
mensional PCA scatter-plot was generated with R software 
Table III. Differences in the expression levels of the 5 selected 
genes among the patients with glioblastoma, belonging to the 
short (n=10) or long (n=9) RFS groups.
 RFS (mean)
 ----------------------------------------------
Gene Short Long P-value
miRNA-150-5p 0.075 0.192 0.040a
miRNA-328-3p 0.042 0.192 0.060
SELE 0.006 0.000 0.094
SELL 0.027 0.010 0.076
ADAMTS13 0.013 0.002 0.059
RFS, recurrence-free survival; mean, mathematical mean of 2-ΔCT gene 
expression levels within the group; aP<0.05. miRNA, microRNA; 
SELE, selectin E; SELL, selectin L; ADAMTS13, a disintegrin and 
metalloproteinase with thrombospondin type 1 motif, member 13.
  
Figure 1. Scatter-plot of principal component analysis. Visualization 
in a tridimensional space of the discriminative power of the expres-
sion levels of the 5 selected genes (microRNA-150-5p and -328-3p, 
selectin E and L, and a disintegrin and metalloproteinase with 
thrombospondin type 1 motif, member 13), considered as variables, in 
correctly classifying the 19 GB samples included in the present study 
into their corresponding short or long RFS group. The black and red 
dots represent the 10 short and 9 long RFS GB samples, respectively. 
GB, glioblastoma; RFS, recurrence-free survival; Comp., component.
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(R Foundation for Statistical Computing, Vienna, Austria; 
https://www.r-project.org/).
Leave-one-out cross-validation (LOOCV) was used as 
resampling method to estimate the prediction error of the 
model. Its indicator, the error rate, defined as 1 ‑ accuracy 
rate, states the probability of misclassification of a classifier. 
In LOOCV, 1 instance is eliminated from the dataset, and 
the classifier is created on the remaining instances, in order 
to assess the correctness of the prediction of the eliminated 
instance. This process is then repeated for all the instances.
Logistic regression analysis was performed using Stata 
SE12.0 software (StataCorp LP, College Station, USA), 
considering short/long RFS group as the dependent variable, 
and the area of the tumor and the patient's age and gender as 
the independent variables.
Results
Demographic characteristics of the patients and molecular 
characterization of the tumors. Patients with GB were classi-
fied in 2 groups, based on their duration of RFS: Patients were 
defined as short RFS, if RFS = <6 months, and long RFS, if 
RFS = >14 months.
The comparison between the patient's characteristics, 
including age, gender and localization of the tumor, and the 
2 lengths of RFS, did not identify any significant associations 
(data not shown). The calculated average tumor area was 
smaller in the long RFS group compared with the short RFS 
group (38 vs. 58 cm2, respectively; Table II), but this differ-
ence was not observed to be statistically significant (data 
not shown).
Table IV. Classification of observations based on the derived discriminant functions.
A, Classification
 Predicted RFS, n (%)
 ---------------------------------------------------------------------------------------------
Actual RFS Actual RFS, total n Short Long
Short 10   9 (90) 1 (10)
Long  9 0 (0)   9 (100)
B, Probabilities
Surgical pathology number Actual RFS group Predicted RFS group Prob. Second predicted RFS group Prob.
298/09 Short  Short 0.9989 Long 0.0011
476/06 Long  Long 0.9912 Short 0.0088
2102/08 Long  Long 0.9872 Short 0.0128
3605/06 Short  Short 0.9992 Long 0.0008
4096/10 Short  Short 0.8672 Long 0.1328
4239/12 Short  Short 0.6459 Long 0.3541
4318/07 Long  Long 0.9998 Short 0.0002
4382/05 Short  Short 0.9962 Long 0.0038
4534/11 Long  Long 0.5913 Short 0.4087
4561/12 Long  Long 0.8025 Short 0.1975
4619/07 Long  Long 0.6960 Short 0.3040
5165/11 Long  Long 0.9139 Short 0.0861
6043/08 Long  Long 0.9152 Short 0.0848
7031/07 Long  Long 0.9983 Short 0.0017
7624/05 Short  Short 0.9909 Long 0.0091
7901/09 Short  Short 0.9753 Long 0.0247
9298/07 Short  Short 0.8214 Long 0.1786
9303/09 Short   Longa 0.5591  Shorta 0.4409
10504/10 Short  Short 0.9618 Long 0.0382
Using 19 GB cases, a 5-genes combination approach was developed, in order to discriminate among the 2 types of RFS, short and long 
(considered as the classification variable), displayed by the patients. The 5 predictor variables entered were the gene expression levels of 
microRNA-150-5p and -328-3p, selectin E and L, and a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13. Of 
the 19 observations used, 18 (94.7%) were correctly classified (P=0.0079; a refers to the observations that were incorrectly classified). The 
actual, predicted and second predicted (non-predicted) statistical probability calculated for each GB sample of belonging to the short or long 
RFS group, is also indicated. RFS, recurrence-free survival; Prob., probability; GB, glioblastoma.
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Furthermore, using logistic regression analysis, the role of 
potential interference factors, including the patient's age, size 
of the tumor and extent of surgery, were excluded from the 
short/long RFS classification (data not shown).
Molecular markers. Codon 132 in the IDH1 gene was confirmed 
to be wild-type in all the 19 GB samples analyzed, while 
9/19 (44%) GB samples presented with EGFR amplification, 
and 3/9 (33%) samples carried the EGFRvIII variant (Table I). 
Among the short RFS samples, 3/10 (30%) cases presented 
with EGFR amplification, and 1/3 (33%) carried the EGFRvIII 
variant; whereas in the long RSF samples, 6/9 (67%) cases 
presented with EGFR amplification, and 2/6 (33%) carried the 
EGFRvIII variant (Table I). Overall, 8/19 (42%) GB samples 
exhibited MGMT promoter methylation, 5 of which belonged 
to the 10 short RFS group (50%), whereas only 3 (33%) of 
those samples with MGMT promoter methylation belonged to 
the 9 long RSF group (Table I).
Molecular markers and RFS association analysis. The 
comparison between the frequencies of alterations in the 
molecular marker that were identified in the patients with 
GB, and the differences in RFS displayed by these patients, 
did not reveal any significant differences. Furthermore, no 
significant correlations were observed among all the molec-
ular alterations analyzed.
PCR array data and RFS association analysis. The differences 
between the short and long RFS groups, regarding the expres-
sion levels and copy number of 191 genes, were analyzed using 
3 PCR arrays. The results revealed significant differences in 
the expression levels of miRNA-150-5p between the 2 groups 
(P=0.040; Table III).
5-genes combination. In order to perform a discriminant 
analysis and predict the probability of a GB case to belong to 
the short or long RFS group, based on their gene expression 
levels, 5 genes with the lowest P-value (P<0.095), including 
miRNA-150-5p and -328-3p, selectin E (SELE) and L (SELL), 
and a disintegrin and metalloproteinase with a thrombos-
pondin type 1 motif, member 13 (ADAMTS13), were selected 
for the analysis (Table III).
The combination of the expression levels of the above 5 genes 
was able to correctly classify the GB samples into their corre-
sponding short or long RFS group, with a precision of 90 and 
100%, respectively (Table IV). Overall, 94.74% (18/19) GB 
cases were correctly classified with this method (P=0.008; 
Table IV). The probability of each sample to belong to one 
or the other group is also indicated in Table IV. Among the 
18 samples correctly classified, 12 (66%) were assigned a 
probability >90%, including 7 cases (34%) whose probability 
was >99% (Table IV). Using the expression levels of the afore-
mentioned 5 selected genes (miRNA150-5p, miRNA328-3p, 
SELE, SELL and ADAMTS13) as data variables, a PCA was 
performed, which clearly indicated a well‑defined separation 
of the 2 RFS populations in a tridimensional space (Fig. 1).
Cross-validation of the 5-genes combination. The prediction 
error of the 5-genes combination approach was estimated 
via cross-validation, using a resampling method. In this type 
of methodology, the prediction error is calculated for each 
measured tree from a presumed distribution of errors, and a 
dataset is subsequently generated as the sum of a prediction 
and a random prediction error.
The percentage of cases correctly classified following 
this method was 90% (9/10) in the short RFS samples, and 
78% (7/9) in the long RFS samples, with a total error rate 
of 0.1579 (Table V).
Discussion
In regards to GB, it is of importance to identify key molecular 
markers, and to perform simple and prompt molecular diag-
nostic tests that are able to predict the survival time and 
therapeutic response of patients. In the present study, a wide 
molecular characterization, including analysis of miRNA, 
RNA and DNA, was performed on 19 GB cases with different 
RFS outcome, in an attempt to better understand the dynamics 
of the genomic alterations associated with relapse in patients 
with GB. A long-term recurrence GB group, with an RFS 
ranging from 14 to 71 months (mean RFS = 27 months), was 
included in the study. This group represents rare cases of GB, 
compared with the GB RFS reported in the literature (3).
Based on the clinical history of the patients and the 
molecular features of their tumors, all the cases were clas-
sified as primary GBs. The patients did not present any 
previous records of brain neoplasm, and their median age 
at the time of diagnosis was 60 years, which is in agreement 
with previous studies that reported the mean age of patients 
clinically diagnosed with primary GB to be 62 years, and 
45 years in the case of patients clinically diagnosed with 
secondary GB (18). In addition, the patients of the present 
Table V. Overall cross-validation error rate.
A, Value prediction
RFS Recall 1-precision
Short 0.9000 0.1818
Long 0.7778 0.1250
B, Confusion matrix
RFS Short Long Total
Short  9 1 10
Long  2 7   9
Total 11 8 19
Overall cross-validation of the 5-genes combination approach using 
the leave-one-out method. Recall is the percentage of correctly 
predicted instances, whereas 1-precision is the percentage of actual 
errors among all the encounters classified as errors. The error rate 
is the percentage of datasets that are incorrectly classified by the 
method, which corresponds to the probability of misclassification 
of a classifier. The error rate of this 5-genes combination approach 
was determined to be 0.1579 for the predicted values. RFS, recur-
rence-free survival.
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study exhibited a high frequency of overexpression of EGFR 
(44%) and absence of IDH1 mutations, which are typical 
features of primary GBs (18).
The expression levels of 84 miRNAs whose expression 
pattern is altered during nervous system-associated carcino-
genesis, and 84 genes whose products are involved in cell-cell 
and cell-matrix interaction processes, were evaluated by qPCR 
array. Additionally, a copy number PCR array analysis was 
performed on 23 genes whose expression pattern has been 
reported to be frequently altered in human glioma tumors (15). 
The results revealed significant differences in the expression 
levels of miRNA150-5p between the short and long RFS groups.
The 5 genes with the highest differences in gene expres-
sion levels that were identified in the study, including 
miRNA150-5p, miRNA328-3p, SELE, SELL and 
ADAMTS13, were selected for subsequent analysis, despite 
their P-values were not significant (P<0.095). The resulting 
5-genes combination approach was able to correctly classify 
94.74% of the 19 GB samples into their corresponding short 
or long RFS groups. To the best of our knowledge, the expres-
sion pattern of the above 5 genes has never been associated 
with RFS in GB thus far.
Next, an LOOCV was performed to evaluate the perfor-
mance of this 5-genes combination approach, and a low error 
rate (0.1579) was obtained for this method, indicating that 
84% of the 19 GB cases were correctly classified following 
this approach.
Of the aforementioned genes, SELE, SELL and ADAMTS13 
were observed to be overexpressed in the short RFS GB samples, 
which is the group with the worst prognosis. ADAMTS13 has 
been previously associated with the degradation and remod-
eling of the ECM, while SELE and SELL are cell adhesion 
molecules (CAMs) that mediate cell attachment, migration and 
signaling to and from the ECM (15). Alterations of CAMs have 
been reported to be common in cancer, where the disruption 
of cell-cell or cell-ECM adhesion significantly contributes to 
uncontrolled cell proliferation and progressive distortion of the 
architecture of normal tissue (19). Furthermore, alterations in 
CAMs have been involved in tumor dissemination, since the 
loss of cell-cell adhesion enables the malignant cells to detach 
and subsequently migrate from the primary mass (19).
By contrast, miRNA-150-5p and 328-3p were observed to 
be overexpressed in the long RFS GB group, which is the group 
with the best prognosis. Previous studies have demonstrated that 
the increased expression of miR-150 inhibited breast cancer cell 
migration and invasion in vitro, and decreased cell proliferation 
and induced apoptosis in natural killer and T-cells (20,21). A 
previous study revealed that patients with GB whose expression 
levels of miR-328 were lower than the median value, exhibited 
poor survival, since miR-328 is associated with the cell cycle 
progression (22). Therefore, the ectopic expression of miR-328 
in GB cells may suppress cell proliferation (22).
In the present study, the GB samples were divided and 
compared, according to their short or long RFS time, despite not 
being 2 distinct clinical or pathological entities. All the patients 
with GB displayed the same histological and pathological 
features, including high malignancy, invasive behavior and poor 
prognosis, regardless of their short or long RFS. Therefore, 
it is not easy to differentiate between short and long RFS in 
patients with GB. However, it is of importance to understand 
the mechanisms leading to aggressive GB tumors with high 
spreading capacities, which are not susceptible to standard 
treatments, including surgery, radiotherapy and chemotherapy, 
whereas other GB tumors are more manageable, and enable 
patients to live >1 year. Although tumor invasion and metastasis 
are known to be the main causes of mortality in patients with 
solid cancer, including GB, the characterization of the molecular 
and cellular mechanisms behind these processes is limited.
In conclusion, the present study has demonstrated that 
alterations in the expression pattern of certain miRNAs, 
mRNAs and genomic DNA constitute a particular molecular 
hallmark, which may increase or reduce the aggressive 
behavior of GB tumors, thus influencing the survival time, 
response to therapy and tendency to experience a tumor 
relapse of patients with GB. In particular, the 5-genes 
combination approach performed in the present study was 
able to correctly predict the short or long RFS outcome in 
the majority of patients with GB. The high sensitivity and 
precision of this approach, as confirmed by LOOCV, provide 
a strong foundation for further validation of the association 
between alterations in the expression of the aforementioned 
5 genes and the RFS of patients with GB in a larger population.
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